文献速递肝病消化道肿瘤与早癌消化道出血

非肿瘤性门静脉血栓在肝硬化合并首次诊断肝细胞癌患者自然史中的作用

Role of nonneoplastic PVT in the natural history of patients with cirrhosis and first diagnosis of HCC.
PubMed 文献 · Hepatology · 2023-07-17

该回顾性研究纳入750例接受腹腔镜消融的肝硬化合并肝细胞癌患者,其中88例存在门静脉血栓。分析显示,肝细胞癌诊断时门静脉血栓的发生与治疗前总肿瘤体积(p<0.001)及临床显著门静脉高压(p=0.005)相关;门静脉血栓的存在与较低总生存期独立相关,尤其当血栓进展或闭塞时(p<0.001)。

要点

  • 肝细胞癌诊断时门静脉血栓的发生与治疗前总肿瘤体积及临床显著门静脉高压相关。
  • 门静脉血栓的存在与较低总生存期独立相关,尤其当血栓进展或闭塞时。
  • 进展性和闭塞性门静脉血栓与肝细胞癌相关及非肝细胞癌相关死亡的竞争风险增高相关。

核心结论

  • 肝细胞癌是肝硬化患者门静脉血栓发生和进展的独立危险因素。
  • 进展性和闭塞性门静脉血栓似乎是死亡的独立相关因素,应考虑对该并发症进行筛查和及时治疗。

研究设计与样本

  • 回顾性评估连续接受腹腔镜消融的肝硬化合并肝细胞癌患者,随访至36个月。
  • 共纳入750例患者,其中88例存在门静脉血栓。
  • 门静脉血栓按管腔占据程度(≤50%、>50%但<100%、=100%)及延伸至其他静脉进行分类。
  • 血栓演变在诊断后1年时评估。

主要发现

  • 多因素分析显示,肝细胞癌诊断时门静脉血栓的发生与治疗前总肿瘤体积(p<0.001)和临床显著门静脉高压(p=0.005)相关。
  • 随访期间发生46例新发门静脉血栓,其中27/46(58.7%)存在存活肿瘤。
  • 在肝细胞癌背景下诊断的115例门静脉血栓中,83例有可用的影像学随访,22例接受了抗凝治疗。
  • 在未抗凝患者中,「完全/进展」演变模式与肝细胞癌治疗无应答相关。
  • 门静脉血栓的存在与较低总生存期独立相关,尤其当血栓进展或闭塞时(p<0.001)。

临床怎么用

  • 作者认为,应考虑对进展性和闭塞性门静脉血栓进行筛查和及时治疗。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND AND AIMS: HCC can increase the risk of nonneoplastic PVT in cirrhosis. However, the natural history of PVT and its prognostic role in HCC patients are unknown. APPROACH AND RESULTS: Consecutive HCC patients with cirrhosis undergoing laparoscopic ablation were retrospectively evaluated and followed up to 36 months. HCC and PVT characteristics and evolution were reviewed. PVT was categorized according to lumen occupancy (≤50%, >50% <100%, and = 100%) and extension to other veins. The evolution of thrombosis was considered at 1 year from diagnosis. Variables associated with the presence of PVT and evolution patterns were analyzed, as well as their impact on survival. In all, 750 patients were included, 88 of whom had PVT. On multivariate analysis, the occurrence of PVT at HCC diagnosis was associated with pretreatment total tumor volume ( p < 0.001) and clinically significant portal hypertension ( p = 0.005). During the follow-up, 46 de novo PVT occurred, 27/46 (58.7%) in the presence of a viable tumor. Among 115 PVT diagnosed in the presence of HCC, 83 had available radiological follow-up, and 22 were anticoagulated. The "complete/progressive" evolution pattern was associated with nonresponse to HCC treatment in non-anticoagulated patients. The presence of PVT was independently associated with lower overall survival, particularly when progressive or occlusive ( p < 0.001). A higher competing risk of death emerged for "complete and progressive" PVT, both for HCC-related ( p < 0.001) and non-HCC-related ( p = 0.002) death. CONCLUSIONS: HCC represents an independent risk factor for the occurrence and progression of PVT in cirrhosis. Since progressive and occlusive PVT seems to be an independent factor associated with mortality, screening and prompt treatment of this complication should be considered.

来源:Hepatology,查看原文。版权归原作者所有。

引用

  1. Senzolo M, Shalaby S, Grasso M, et al. Role of nonneoplastic PVT in the natural history of patients with cirrhosis and first diagnosis of HCC. Hepatology. 2023. PMID: 37505218. doi:10.1097/HEP.0000000000000538

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。